CASE STUDY

Execution at Speed: FPFV <100 Days, Enabling Next-Stage Funding

Speed, precision, and readiness—REV Clinical accelerates trials when it matters most.

Study Details

- Phase: Phase 1/2 Study
- Indication: Solid Tumor / Advanced Melanoma
- Patients: 20 (Phase 1a – Dose Escalation); 40 (Phase 1b – Dose Expansion); 20 (Phase 2 – Advanced melanoma)
- No of Sites: 12 sites
- Country of Execution: USA

The Challenge

Sponsor initiated a U.S. Phase 1 oncology study with limited seed funding and required rapid generation of initial safety data to support the next financing round, while seeking a lean, agile partner capable of delivering cost-efficient, high-impact clinical execution solutions.

Strategic Approach & Execution

- Pre-Activated Network: Leveraged REV Clinical Velocity Network with Master NDAs to eliminate contracting delays.
- Rapid Site Expansion: Onboarded 2 community oncology sites with Central IRB readiness, activated within ~2 months.
- EDC Acceleration: Used standardized eCRF library to achieve EDC go-live in 6 weeks.
- Safety Optimization: Integrated local labs for faster, real-time safety assessments.
- 1-Day Activation: Enabled site activation within 1 working day post-SIV through proactive readiness.
- Pre-Screened Enrollment: Initiated patient pre-screening pre-activation to drive Day 1 recruitment momentum.

Outcome & Impact

- FPFV achieved in <100 days
- Reduced site startup timelines by ~40–60%
- Accelerated enrollment curve from first site activation
- Enhanced sponsor confidence leading to next-stage funding readiness